Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alefacept in New Onset Type 1 Diabetes
NCT00965458Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of alefacept in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2011; status: terminated.
02
Drugs
alefacept
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00965458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965458.